<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35351818</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1533-3450</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>29</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the American Society of Nephrology : JASN</Title>
          <ISOAbbreviation>J Am Soc Nephrol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Brief Early Life Angiotensin-Converting Enzyme Inhibition Offers Renoprotection in Sheep with a Solitary Functioning Kidney at 8 Months of Age.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">ASN.2021111534</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1681/ASN.2021111534</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Children born with a solitary functioning kidney (SFK) are predisposed to develop hypertension and kidney injury. Glomerular hyperfiltration and hypertrophy contribute to the pathophysiology of kidney injury. Angiotensin-converting enzyme inhibition (ACEi) can mitigate hyperfiltration and may be therapeutically beneficial in reducing progression of kidney injury in those with an SFK.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">SFK was induced in male sheep fetuses at 100 days gestation (term=150 days). Between 4 and 8 weeks of age, SFK lambs received enalapril (SFK+ACEi; 0.5mg/kg per day, once daily, orally) or vehicle (SFK). At 8 months, we examined BP, basal kidney function, renal functional reserve (RFR; GFR response to combined amino acid and dopamine infusion), GFR response to nitric oxide synthase (NOS) inhibition, and basal nitric oxide (NO) bioavailability (basal urinary total nitrate and nitrite [NOx]).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">SFK+ACEi prevented albuminuria and resulted in lower basal GFR (16%), higher renal blood flow (approximately 22%), and lower filtration fraction (approximately 35%), but similar BP, compared with vehicle-treated SFK sheep. Together with greater recruitment of RFR (approximately 14%) in SFK+ACEi than SFK animals, this indicates a reduction in glomerular hyperfiltration-mediated kidney dysfunction. During NOS inhibition, the decrease in GFR (approximately 14%) was greater among SFK+ACEi than among SFK animals. Increased (approximately 85%) basal urinary total NOx in SFK+ACEi compared with SFK animals indicates elevated NO bioavailability likely contributed to improvements in kidney function and prevention of albuminuria.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Brief and early ACEi in SFK is associated with reduced glomerular hyperfiltration-mediated kidney disease up to 8 months of age in a sheep model.</AbstractText>
          <CopyrightInformation>Copyright Â© 2022 by the American Society of Nephrology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>McArdle</LastName>
            <ForeName>Zoe</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Program, Monash Biomedicine Discovery Institute and Department of Physiology, Monash University, Melbourne, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Reetu R</ForeName>
            <Initials>RR</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Program, Monash Biomedicine Discovery Institute and Department of Physiology, Monash University, Melbourne, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bielefeldt-Ohmann</LastName>
            <ForeName>Helle</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>School of Veterinary Science, The University of Queensland, Gatton, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moritz</LastName>
            <ForeName>Karen M</ForeName>
            <Initials>KM</Initials>
            <AffiliationInfo>
              <Affiliation>Child Health Research Centre and School of Biomedical Sciences, University of Queensland, Brisbane, Queensland, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schreuder</LastName>
            <ForeName>Michiel F</ForeName>
            <Initials>MF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Nephrology, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Denton</LastName>
            <ForeName>Kate M</ForeName>
            <Initials>KM</Initials>
            <Identifier Source="ORCID">0000-0002-5929-4387</Identifier>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Program, Monash Biomedicine Discovery Institute and Department of Physiology, Monash University, Melbourne, Victoria, Australia Kate.Denton@monash.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Am Soc Nephrol</MedlineTA>
        <NlmUniqueID>9013836</NlmUniqueID>
        <ISSNLinking>1046-6673</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">angiotensin converting enzyme inhibition</Keyword>
        <Keyword MajorTopicYN="N">glomerular hyperfiltration</Keyword>
        <Keyword MajorTopicYN="N">kidney disease</Keyword>
        <Keyword MajorTopicYN="N">nitric oxide bioavailability</Keyword>
        <Keyword MajorTopicYN="N">renal functional reserve</Keyword>
        <Keyword MajorTopicYN="N">solitary functioning kidney</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>30</Day>
          <Hour>5</Hour>
          <Minute>40</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35351818</ArticleId>
        <ArticleId IdType="doi">10.1681/ASN.2021111534</ArticleId>
        <ArticleId IdType="pii">ASN.2021111534</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
